Small Molecules

27 May 2017 Novartis receives FDA approval for expanded use of Zykadia® in first-line ALK-positive metastatic non-small cell lung cancer (NSCLC)
26 May 2017 Health Canada Grants Approval for Ocaliva™ (obeticholic acid) for the Treatment of Patients with Primary Biliary Cholangitis (PBC)
26 May 2017 Hovione Announces Start of Phase 1 Clinical Trial of HY02, a Proprietary Minocycline Sterile Ointment to Treat a Subset of Anterior Ocular Inflammation
26 May 2017 Phoenix Molecular Designs Announces New Preclinical Data for Targeted Triple Negative Breast Cancer (TNBC) Therapy
26 May 2017 Phase 1 Safety Study Supports Planned Development of PCM-075 in AML
26 May 2017 BioCryst Reports Additional Positive Results From the Second Interim Analysis of Its APeX-1 Trial
26 May 2017 New data at ATS add to the body of evidence for Roche’s Esbriet (pirfenidone) in idiopathic pulmonary fibrosis (IPF)
25 May 2017 Puma Biotechnology Receives FDA Advisory Committee Support for Neratinib
24 May 2017 TRACON Doses First Patient in Phase 1/2 Study of TRC253 in Patients with Prostate Cancer
24 May 2017 Akebia Initiates Phase 2 FO2RWARD Study of Vadadustat in Dialysis Patients with Anemia Related to Chronic Kidney Disease Hyporesponsive to Treatment with Erythropoiesis-Stimulating Agents
24 May 2017 Plazomicin Granted FDA Breakthrough Therapy Designation
24 May 2017 Neurocrine Announces Phase II Results of VMAT2 Inhibitor INGREZZA® For Treatment of Tourette Syndrome
24 May 2017 Biogen’s FAMPYRA® Granted Standard Marketing Authorization in European Union for Improvement of Walking in People with MS
23 May 2017 Aprea Therapeutics Announces First Patients Enrolled in Phase Ib/II Clinical Study of APR-246 for the Treatment of Myelodysplastic Syndrome
23 May 2017 Churchill Pharmaceuticals Announces Submission of NDA for Novel Oral Formulation of Prostate Cancer Treatment
23 May 2017 Sunovion Announces Positive Results from Pivotal Study Evaluating Novel Drug Candidate Dasotraline in Adults with Binge Eating Disorder at Annual American Psychiatric Association Meeting
22 May 2017 Attune Pharmaceuticals Announces Positive Data from Recent Pre-Clinical Studies for ATN-249, an Oral Plasma Kallikrein Inhibitor for the Treatment of HAE at C1-INH Deficiency Workshop
22 May 2017 Adamas Presents Positive Phase 1a Data of ADS-4101 (lacosamide) for the Treatment of Partial Onset Seizures in Epilepsy
22 May 2017 Otsuka Announces Results of Phase 3 Data on Tolvaptan
22 May 2017 Merck Announces Presentation of Phase 2 Results for MK-7264, an Investigational, P2X3 Receptor Antagonist, Being Evaluated for the Treatment of Chronic Cough
22 May 2017 Celgene Announces Positive Results from RADIANCE, the Second Pivotal Phase III Trial of Oral Ozanimod in Patients with Relapsing Multiple Sclerosis
22 May 2017 Results of ATHOS-3 Phase 3 Study of LJPC-501 Published in The New England Journal of Medicine
21 May 2017 Amicus Therapeutics Announces Planned Analysis of Primary Endpoints in Phase 3 Epidermolysis Bullosa Study
21 May 2017 AB Science presents phase 3 data for masitinib in amyotrophic lateral sclerosis (ALS) at the European Network for the Cure of ALS (ENCALS) annual meetin
21 May 2017 Novartis receives positive CHMP opinion for first-line use of Zykadia® in ALK-positive advanced non-small cell lung cancer (NSCLC)

La Merie Biologics

FREE Weekly News Bulletin

2016 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing